Your browser doesn't support javascript.
loading
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Cheah, C Y; Chihara, D; Horowitz, S; Sevin, A; Oki, Y; Zhou, S; Fowler, N H; Romaguera, J E; Turturro, F; Hagemeister, F B; Fayad, L E; Wang, M; Neelapu, S S; Nastoupil, L J; Westin, J R; Rodriguez, M A; Samaniego, F; Anderlini, P; Nieto, Y; Fanale, M A.
  • Cheah CY; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA Department of Haematology, Pathwest Laboratory Medicine WA and Sir Charles Gairdner Hospital, Nedlands School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Australia.
  • Chihara D; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Horowitz S; Department of Pharmacy.
  • Sevin A; Department of Pharmacy.
  • Oki Y; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Zhou S; Department of Biostatistics.
  • Fowler NH; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Romaguera JE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Turturro F; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Hagemeister FB; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Fayad LE; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Wang M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Neelapu SS; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Nastoupil LJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Westin JR; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Rodriguez MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Samaniego F; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Anderlini P; Department of Stem Cell Transplant and Cellular Therapies, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Nieto Y; Department of Stem Cell Transplant and Cellular Therapies, The University of Texas MD Anderson Cancer Center, Houston, USA.
  • Fanale MA; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, USA mfanale@mdanderson.org.
Ann Oncol ; 27(7): 1317-23, 2016 07.
Article en En | MEDLINE | ID: mdl-27091808
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Inmunoconjugados / Resistencia a Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin / Inmunoconjugados / Resistencia a Antineoplásicos Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Año: 2016 Tipo del documento: Article